Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease
ACS Chemical Biology · 2025
DOI: 10.1021/acschembio.4c00602 ↗At a glance
Journal article in ACS Chemical Biology, 2025. Written by Senthilkumar Deivasigamani and 12 co-authors. Institution: Esya Ltd., 84 Wood Lane, London W12 0BZ, U.K. Major MEDLINE topics: Alzheimer Disease, Lysosomes, Biomarkers. Cited 3 times so far (Crossref); 86 references. Funded by: Alzheimer's Drug Discovery Foundation, Innovate UK, Michael J. Fox Foundation for Parkinson's Research.
Topics: Demenz
Abstract (original language)
Lysosomal storage disorders (LSDs) and adult neurodegenerative disorders like Alzheimer's disease (AD) share various clinical and pathophysiological features. LSDs are characterized by impaired lysosomal activity caused by mutations in key proteins and enzymes. While lysosomal dysfunction is also linked to AD pathogenesis, its precise role in disease onset or progression remains unclear. Lysosomal ionic homeostasis is recognized as a key feature of many LSDs, but it has not been clinically linked with AD pathology. Thus, investigating whether this regulation is disrupted in AD is important, as it could lead to new therapeutic targets and biomarkers for this multifactorial disease. Here, using two-ion mapping (2-IM) technology, we quantitatively profiled lysosomal pH and Ca2+ in blood-derived monocytes from AD patients and age-matched controls and correlated lysosome ionicity with age and key markers of AD pathology, namely, amyloid deposits, tauopathy, neurodegeneration, and inflammation. Together, the data show that the ionic milieu of lysosomes is dysregulated in monocytes of AD patients and correlates with key plasma biomarkers of AD. Using a machine learning model based on the above parameters, we describe a proof-of-concept combinatorial biomarker platform that accurately distinguishes between patients with AD and control participants with an area under the curve of >96%. Our study introduces a convenient, noninvasive platform with the potential to diagnose Alzheimer's disease based on fluid, cellular, and molecular biomarkers. Further, these findings highlight the potential for investigating therapeutic mechanisms capable of restoring lysosome ionic homeostasis to ameliorate AD.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Esya Ltd., 84 Wood Lane, London W12 0BZ, U.K.
- Neuroscience Department, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
- Department of Chemistry, The University of Chicago, Chicago, Illinois 60637, United States.
- Neuroscience Institute, The University of Chicago, Chicago, Illinois 60637, United States.
- Institute for Biophysical Dynamics, The University of Chicago, Chicago, Illinois 60637, United States.
ORCID profiles: Hernando M Vergara, Jason Uslaner, Yamuna Krishnan, Souvik Modi
Funding
- Alzheimer's Drug Discovery Foundation
- Innovate UK
- Michael J. Fox Foundation for Parkinson's Research
Cite
APA
Deivasigamani, S., Thekkan, S., Vergara, H. M., Conolly, O., Cosden, M., Phan, T., Smith, S., Marcus, J., Uslaner, J., Venkat, D., Drolet, R. E., Krishnan, Y., & Modi, S. (2025). Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease. ACS Chemical Biology. https://doi.org/10.1021/acschembio.4c00602
Vancouver
Deivasigamani S, Thekkan S, Vergara HM, Conolly O, Cosden M, Phan T, et al. Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease. ACS Chemical Biology. 2025. doi:10.1021/acschembio.4c00602
BibTeX
@article{Deivasigamani2025,
author = {Deivasigamani, Senthilkumar and Thekkan, Shareefa and Vergara, Hernando M and Conolly, Owen and Cosden, Mali and Phan, Thienlong and Smith, Sean and Marcus, Jacob and Uslaner, Jason and Venkat, Dhivya and Drolet, Robert E and Krishnan, Yamuna and Modi, Souvik},
title = {Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease},
journal = {ACS Chemical Biology},
year = {2025},
doi = {10.1021/acschembio.4c00602}
}
EUVIMED